Duncan Barbara Gayle
SEC-identified person · CIK 1353128 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Atea Pharmaceuticals, Inc. AVIR | Director | filed 2020 - 2026 |
| Halozyme Therapeutics, INC. Halo | Director | filed 2023 - 2026 |
| Ovid Therapeutics Inc. OVID | Director | filed 2017 - 2026 |
| Fusion Pharmaceuticals Inc. FUSN | Director | filed 2020 - 2024 |
| Jounce Therapeutics, Inc. JNCE | Director | filed 2017 - 2023 |
| Adaptimmune Therapeutics PLC ADAP] | Director | filed 2016 - 2022 |
| Immunomedics INC IMMU | Director | filed 2019 - 2020 |
| Medgenics, INC. MDGN | Director | filed 2015 - 2020 |
| Theravance INC thrx | Director | filed 2016 - 2017 |
| Intercept Pharmaceuticals, INC. ICPT | Chief Financial Officer | filed 2012 - 2016 |
| DOV Pharmaceutical INC DVOP | Director · President and CFO | filed 2006 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.